Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.1691
Open
0.1691
VWAP
0.17
Vol
26.98K
Mkt Cap
3.39M
Low
0.1691
Amount
4.56K
EV/EBITDA(TTM)
--
Total Shares
28.80M
EV
206.51K
EV/OCF(TTM)
--
P/S(TTM)
--
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Show More
Valuation Metrics
The current forward P/E ratio for Azitra Inc (AZTR.A) is -0.20, compared to its 5-year average forward P/E of -3.10. For a more detailed relative valuation and DCF analysis to assess Azitra Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.10
Current PE
-0.20
Overvalued PE
2.96
Undervalued PE
-9.16
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
214.43
Current PS
0.00
Overvalued PS
801.87
Undervalued PS
-373.02
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+4.68%
-3.10M
Operating Profit
FY2025Q1
YoY :
+4.62%
-3.07M
Net Income after Tax
FY2025Q1
YoY :
+53.33%
-0.23
EPS - Diluted
FY2025Q1
YoY :
+1.68%
-3.07M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
630.0K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
1
630.0K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AZTR News & Events
Events Timeline
2025-07-18 (ET)
2025-07-18
22:20:00
Azitra files to sell 2.25M shares of common stock for holders
2025-06-17 (ET)
2025-06-17
08:05:25
Azitra's ATR12-351 shows safety in Phase 1b Netherton syndrome trial
2025-04-24 (ET)
2025-04-24
16:09:55
Azitra enters share purchase agreement with Alumni Capital LP
Sign Up For More Events
Sign Up For More Events
News
9.0
06-17NewsfilterAzitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
1.0
06-10NewsfilterAzitra, Inc. Announces Presentation at the 2025 BIO International Convention
9.0
05-28NewsfilterAzitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
Sign Up For More News
People Also Watch
AQB
AquaBounty Technologies Inc
0.760
USD
+1.60%
BQ
Boqii Holding Ltd
2.520
USD
-0.40%
ICON
Icon Energy Corp
2.053
USD
-9.56%
SHPH
Shuttle Pharmaceuticals Holdings Inc
3.420
USD
0.00%
QLGN
Qualigen Therapeutics Inc
1.760
USD
-3.30%
TRNR
Interactive Strength Inc
4.108
USD
-2.42%
SCNI
Scinai Immunotherapeutics Ltd
1.500
USD
-1.32%
GNLN
Greenlane Holdings Inc
3.840
USD
+17.79%
FAQ
What is Azitra Inc (AZTR) stock price today?
The current price of AZTR is 0.164 USD — it has increased 0 % in the last trading day.
What is Azitra Inc (AZTR)'s business?
What is the price predicton of AZTR Stock?
What is Azitra Inc (AZTR)'s revenue for the last quarter?
What is Azitra Inc (AZTR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Azitra Inc (AZTR)'s fundamentals?
How many employees does Azitra Inc (AZTR). have?